Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation-positive non-squamous non-small cell lung cancer (NSCLC): An open-label randomized trial

Author(s): Kato T, Seto T, Nishio M, Goto K, Atagi S, et al.


Background: Resistance to first-generation or second-generation EGFR tyrosine kinase inhibitor (TKI) monotherapy develops in almost half of patients with EGFR-positive non-small-cell lung cancer (NSCLC) after 1 year of treatment. The JO25567 phase 2 trial comparing erlotinib plus bevacizumab combination therapy with erlotinib monotherapy established the activity and manageable toxicity of erlotinib plus bevacizumab in patients with NSCLC. We did a phase 3 trial to validate the results of the JO25567 study and report here the results from the preplanned interim analysis.

Methods: In this prespecified interim analysis of the randomised, open-label, phase 3 NEJ026 trial, we recruited patients with stage IIIB-IV disease or recurrent, cytologically or histologically confirmed non-squamous NSCLC with activating EGFR genomic aberrations from 69 centres across Japan. Eligible patients were at least 20 years old, and had an Eastern Cooperative Oncology Group performance status of 2 or lower, no previous chemotherapy for advanced disease, and one or more measurable lesions based on Response Evaluation Criteria in Solid Tumours (1.1). Patients were randomly assigned (1:1) to receive oral erlotinib 150 mg per day plus intravenous bevacizumab 15 mg/kg once every 21 days, or erlotinib 150 mg per day monotherapy. Randomisation was done by minimisation, stratified by sex, smoking status, clinical stage, and EGFR mutation subtype. The primary endpoint was progression-free survival. This study is ongoing; the data cutoff for this prespecified interim analysis was Sept 21, 2017. Efficacy was analysed in the modified intention-to-treat population, which included all randomly assigned patients who received at least one dose of treatment and had at least one response evaluation. Safety was analysed in all patients who received at least one dose of study drug. The trial is registered with the University Hospital Medical Information Network Clinical Trials Registry, number UMIN000017069.

Similar Articles

Distribution of distant metastases from newly diagnosed non-small cell lung cancer

Author(s): Quint LE, Tummala S, Brisson LJ, Francis IR, Krupnick AS, et al.

Breast metastases from extramammary malignancies

Author(s): Bohman L, Bassett L, Gold R, Voet R

Metastases to the breast from extramammary malignancies

Author(s): Amichetti M, Perani B, Boi S

Metastatic tumors to the breast: Mammographic and ultrasonographic findings

Author(s): Lee SH, Park JM, Kook SH, Han BK, Moon WK

Metastases to the breast: Differential diagnosis from primary breast carcinoma

Author(s): Vergier B, Trojani M, De Mascarel I, Coindre JM, Le Treut A

Metastasis of primary lung carcinoma to the breast: a systematic review of the literature

Author(s): Mirrielees JA, Kapur JH, Szalkucki LM, Harter JM, Salkowski LR, et al.

EGFR-Mutated Breast Metastasis of Lung Adenocarcinoma: A Case Report

Author(s): Dansin E, Carnot A, Servent V, Daussay D, Robin YM, et al.

NCCN guidelines insights: Non-small cell lung cancer

Author(s): Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, et al.

Metastases to the breast from extramammary carcinomas

Author(s): Nielsen M, Ørnvold K, Andersen Ja, HenriksenFw, Kristensen Pb, et al.

Metastasis to the breast from extramammary malignancies: A report of four cases and a review of literature

Author(s): Vizcaino I, Torregrosa A, Higueras V, Morote V, Cremades A, et al.

Metastases to breast from primary lung cancer

Author(s): Babu KS, Roberts F, Bryden F, McCafferty A, Downer P, et al.

Local treatment of oligometastatic recurrence in patients with resected non-small cell lung cancer

Author(s): Yano T, Okamoto T, Haro A, Fukuyama S, Yoshida T, et al.

Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer

Author(s): Parikh RB, Cronin AM, Kozono DE, Oxnard GR, Mak RH, et al.

A case of metachronous metastasis to the breast from non-small cell lung carcinoma

Author(s): Yoon MY, Song CS, Seo MH, Kim MJ, Oh TY, et al.